Found: 216
Select item for more details and to access through your institution.
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
- Published in:
- EJHaem, 2024, v. 5, n. 5, p. 940, doi. 10.1002/jha2.968
- By:
- Publication type:
- Article
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01159-8
- By:
- Publication type:
- Article
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 4, p. 465, doi. 10.1111/ejh.14254
- By:
- Publication type:
- Article
Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study.
- Published in:
- Journal of Surgical Oncology, 2012, v. 105, n. 7, p. 679, doi. 10.1002/jso.22101
- By:
- Publication type:
- Article
Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?
- Published in:
- Psycho-Oncology, 2013, v. 22, n. 10, p. 2313, doi. 10.1002/pon.3284
- By:
- Publication type:
- Article
Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E253, doi. 10.1002/ajh.26191
- By:
- Publication type:
- Article
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 11, p. E473, doi. 10.1002/ajh.24533
- By:
- Publication type:
- Article
Multiples Myelom: Korrelation zwischen minimaler Resterkrankung und progressionsfreiem Überleben.
- Published in:
- Kompass Onkologie, 2023, v. 10, n. 1, p. 17, doi. 10.1159/000529718
- By:
- Publication type:
- Article
European Perspective on Multiple Myeloma Treatment Strategies in 2014.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
European Perspective on Multiple Myeloma Treatment Strategies in 2014.
- Published in:
- Oncologist, 2014, v. 19, n. 8, p. 829, doi. 10.1634/theoncologist.2014-0042
- By:
- Publication type:
- Article
European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses.
- Published in:
- Oncologist, 2012, v. 17, n. 5, p. 592, doi. 10.1634/theoncologist.2011-0391
- By:
- Publication type:
- Article
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective.
- Published in:
- Oncologist, 2011, v. 16, n. 4, p. 388, doi. 10.1634/theoncologist.2010-0386
- By:
- Publication type:
- Article
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective.
- Published in:
- Oncologist, 2010, v. 15, n. 1, p. 6, doi. 10.1634/theoncologist.2009-0203
- By:
- Publication type:
- Article
Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1168120
- By:
- Publication type:
- Article
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1078725
- By:
- Publication type:
- Article
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1286700
- By:
- Publication type:
- Article
Germline Risk Contribution to Genomic Instability in Multiple Myeloma.
- Published in:
- Frontiers in Genetics, 2019, p. N.PAG, doi. 10.3389/fgene.2019.00424
- By:
- Publication type:
- Article
Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384).
- Published in:
- Cancers, 2023, v. 15, n. 21, p. 5157, doi. 10.3390/cancers15215157
- By:
- Publication type:
- Article
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4667, doi. 10.3390/cancers15184667
- By:
- Publication type:
- Article
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 5996, doi. 10.3390/cancers13235996
- By:
- Publication type:
- Article
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4706, doi. 10.3390/cancers13184706
- By:
- Publication type:
- Article
Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4135, doi. 10.3390/cancers13164135
- By:
- Publication type:
- Article
Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
- Published in:
- Cancers, 2021, v. 13, n. 14, p. 3439, doi. 10.3390/cancers13143439
- By:
- Publication type:
- Article
Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 961, doi. 10.3390/cancers13050961
- By:
- Publication type:
- Article
Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2537, doi. 10.3390/cancers12092537
- By:
- Publication type:
- Article
Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
- Published in:
- Cancers, 2020, v. 12, n. 5, p. 1335, doi. 10.3390/cancers12051335
- By:
- Publication type:
- Article
Growth factors in multiple myeloma: acomprehensive analysis of their expression intumor cells and bone marrow environment usingAffymetrix microarrays.
- Published in:
- BMC Cancer, 2010, v. 10, p. 198, doi. 10.1186/1471-2407-10-198
- By:
- Publication type:
- Article
Microarray-based understanding of normal and malignant plasma cells.
- Published in:
- Immunological Reviews, 2006, v. 210, n. 1, p. 86, doi. 10.1111/j.0105-2896.2006.00362.x
- By:
- Publication type:
- Article
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01126-3
- By:
- Publication type:
- Article
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01121-8
- By:
- Publication type:
- Article
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
- Published in:
- Oncogene, 2005, v. 24, n. 21, p. 3512, doi. 10.1038/sj.onc.1208536
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 385, doi. 10.1016/j.clml.2023.02.006
- By:
- Publication type:
- Article
P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S140, doi. 10.1016/S2152-2650(21)02315-6
- By:
- Publication type:
- Article
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S133, doi. 10.1016/S2152-2650(21)02304-1
- By:
- Publication type:
- Article
P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S110, doi. 10.1016/S2152-2650(21)02265-5
- By:
- Publication type:
- Article
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02194-7
- By:
- Publication type:
- Article
P-052: Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S66, doi. 10.1016/S2152-2650(21)02186-8
- By:
- Publication type:
- Article
P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S65, doi. 10.1016/S2152-2650(21)02183-2
- By:
- Publication type:
- Article
P-018: Automatic analysis of magnetic resonance imaging in multiple myeloma patients: deep-learning based pelvic bone marrow segmentation and radiomics analysis for prediction of plasma cell infiltration.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S49, doi. 10.1016/S2152-2650(21)02152-2
- By:
- Publication type:
- Article
P-017: Repeatability and reproducibility of apparent diffusion coefficient measurements of bone marrow in magnetic resonance imaging of multiple myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S48, doi. 10.1016/S2152-2650(21)02151-0
- By:
- Publication type:
- Article
P-012: Automatic bone marrow segmentation in whole-body magnetic resonance imaging: towards comprehensive, objective MRI-phenotypic bone marrow characterization in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S45, doi. 10.1016/S2152-2650(21)02146-7
- By:
- Publication type:
- Article
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
- By:
- Publication type:
- Article
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02097-8
- By:
- Publication type:
- Article
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
- By:
- Publication type:
- Article
OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S5, doi. 10.1016/S2152-2650(21)02081-4
- By:
- Publication type:
- Article
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
- By:
- Publication type:
- Article
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01581-0
- By:
- Publication type:
- Article
Comparison of Granulocyte colony stimulating factor support versus antibiotic prophylaxis in autologous stem cell transplantation in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e292, doi. 10.1016/j.clml.2019.09.480
- By:
- Publication type:
- Article
Health-related quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e290, doi. 10.1016/j.clml.2019.09.477
- By:
- Publication type:
- Article
Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e144, doi. 10.1016/j.clml.2019.09.240
- By:
- Publication type:
- Article